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A report of the Keystone Symposia joint meetings on
DNA Methylation and Epigenomics held in Keystone,
Colorado, USA, 29 March to 3 April, 2015.Meissner (Harvard University, Broad Institute, USA) dis-Introduction
This year, the Keystone Symposia hosted concurrent
meetings on DNA methylation and epigenomics. Multiple
sessions were jointly held between the two meetings, and
in total the number of participants at both meetings was
one of the largest ever at Keystone. A notable aspect of
the two meetings was the relatively large number of new
and increasingly powerful epigenetic technologies that
have been developed recently, ranging from novel single-
cell epigenetic profiling to ligation-free Hi-C (Table 1).
Many new findings and novel concepts were also dis-
cussed at the meeting, particularly around the epigenetics
of differentiation and development, as well as disease,
pluripotency and stem cells, to name just a few. The
meeting opened with a Keynote Address by Adrian Bird
(University of Edinburgh, UK), who reported on altered
DNA methylation regions in cancer, and brain genomes
that coincide with regions of altered base composition.
AT-rich DNA regions are relatively less methylated,
while CG-rich regions are relatively more methylated,
leading to speculation that base composition in the
genome impacts the methylome. The proteins bound to
DNA are known to influence DNA methylation, and
these proteins are in turn influenced by DNA base
composition.
DNA methylation, differentiation and chromatin
Key questions in epigenetics are what drives cell differ-
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Related to this, how are the patterns of chromatin or
DNA methylation initially primed, and how does genetic
or epigenetic variation impact development? A number
of talks focused on these questions. First, Alexander
cussed targeted DNA methylation as embryonic stem cells
(ESCs) differentiate into the endoderm. Knockout (KO)
of DNA (cytosine-5)-methyltransferase 3A (DNMT3A)
in differentiating ESCs leads to a lack of methylation
acquired de novo at many sites, including genes such as
Nanog and Foxa2. Nonetheless, the cells are still able to
form teratomas when they are injected into mice.
Knockout of both DNMT3A and DNMT3B causes
passage-dependent loss of DNA methylation, albeit at
very slow rates. Interestingly, deletion of DNA (cyto-
sine-5)-methyltransferase 1 (DNMT1) causes cell death
in ESCs. Ryan Lister (University of Western Australia,
Australia) addressed whether de novo methylation occur-
ring in gene promoters is (solely) responsible for gene
silencing. He described epigenetic manipulation in cells by
inducing the expression of a zinc finger-DNMT3A fusion
protein, resulting in high levels of widespread, de novo
methylation of gene promoters. Strikingly, gains in pro-
moter DNA methylation simultaneously coexist with
active histone marks on many gene promoters, and are in-
sufficient to transcriptionally repress most genes. Removal
of zinc finger-DNMT3A overexpression leads to a rapid
return to an unmethylated state. Bing Ren (University of
California, San Diego, USA) described the creation of a
novel, chromosome-spanning haplotype reconstruction
strategy (HaploSeq; Table 1), which revealed extensive al-
lelic biases and considerable variation in both chromatin
state and transcription from identical human tissues in
different individuals. Allelic differences of chromatin state
involve cis-regulatory elements and are associated with al-
lelic differences in transcription factor binding due to local
sequence variations.ioMed Central. This is an Open Access article distributed under the terms of the
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Table 1 Recent technological developments in epigenetics reported at the joint meetings
Technique Description Speaker
Single-cell DNA methylation NA Wolf Reik (Babraham Institute, UK)
Single-cell Hi-C NA Peter Fraser (Babraham Institute, UK)
Ligation-free Hi-C Ligation-free assay for genome-wide chromatin
interactions
Robert Beagrie (MRC Clinical Sciences Centre, UK)
NOMe-seq Assay developed in combination with ChIP-seq
to analyze cancer in patients treated with DNMT
inhibitors
Peter Jones (Van Andel Research Institute, USA)
RAP Method to identify genome-wide localization of
a lncRNA
Mitchell Guttman (California Institute of Technology,
USA)
RAP-MS Method to identify lncRNA-protein interactions Mitchell Guttman
SNP-FISH Technique developed by Arjun Raj and colleagues
to enable allele-specific expression analysis of single
cells, or small groups of cells
Marisa Bartolomei (University of Pennsylvania
Perelman School of Medicine, USA)
HaploSeq Haplotype reconstruction sequencing. In situ
ligation to reconstruct long haplotype blocks
Bing Ren (University of California, San Diego, USA)
NET-seq Approach that exploits the extraordinary stability
of the DNA-RNA-RNA polymerase ternary complex
to capture nascent transcripts directly from live cells
L. Stirling Churchman (Harvard Medical School, USA)
Methylation analysis software for
the DRAGEN Bio-IT processor
Software used to carry out methylation analysis
of a genome in 17 minutes
Joseph Ecker (HHMI/The Salk Institute for
Biological Studies, USA)
ChIP chromatin immunoprecipitation; DNMT DNA methyltransferase; HaploSeq haplotype reconstruction using proximity-ligation and shotgun sequencing; Hi-C
comprehensive detection of chromatin interactions in the mammalian nucleus; IT information technology; lncRNA long non-coding RNA; NA ; NET-seq native
elongating transcript sequencing; NOMe-seq nucleosome occupancy and methylome sequencing; RAP RNA antisense purification; RAP-MS RNA antisense
purification with mass spectrometry; SNP-FISH single nucleotide polymorphism and fluorescence in situ hybridization
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retrotransposons, regulators and remodeling
The establishment (writing), recognition (reading) and
erasing of epigenetic marks in the cell are important
features central to the reversibility of epigenetic modifi-
cations. Retrotransposons in the genome, for example,
are usually heavily methylated and silenced; however, on
some occasions it appears that they are also expressed,
as discussed further on. Furthermore, the folding of
chromosomes into active or inactive domains is at least
in part a phenomenon that is epigenetically regulated.
Elphège P Nora (Gladstone Institute, USA), from the
laboratory of Benoit Bruneau, engineered mouse ESCs
that are completely depleted of transcriptional repressor
CTCF. Using carbon-copy chromatin conformation cap-
ture (5-C) at the Xic locus, they showed that the folding
of chromosomes into topologically associating domains
(TADs) is dependent on CTCF. From this work they
concluded that: (1) CTCF is not essential for short-term
ESC survival; (2) chromosome conformation is continu-
ously driven by the action of CTCF; (3) folding into
TADs is not an intrinsic property of chromosomes; and
(4) that histone H3 trimethyl Lys27 domains in ESCs are
not constrained by CTCF. Joseph Costello (University of
California, San Francisco, USA) reported the widespread
existence of intermediate DNA methylation domains in
eight human cell types from four different tissues. He
reported that intermediate DNA methylation domainsare remarkably consistent across individuals, and con-
served between humans and mice. Intermediate DNA
methylation domains have an average length of 300 bp,
and 70 % of them are independent of allelic status (also
known as patchy methylation). The regions containing
intermediate DNA methylation domains also show inter-
mediate levels of gene transcription and exon usage.
Sriharsa Pradhan (New England Biolabs, USA) reported
on writing, reading and erasing functions associated with
the amino acid Lys142 of DNMT1. The writer enzyme
histone-lysine N-methyltransferase SETD7 induces mono-
methylation of Lys142, leading to proteosomal degrad-
ation of DNMT1. Surprisingly, DNMT1 is also found to
interact specifically with several small inhibitory RNAs,
which bind to the active (catalytic) site of DNMT1,
competitively inhibiting its methylation. Overexpression
of exogenous miRNAs, such as miR-155, leads to aber-
rant genomic DNA methylation, resulting in hypome-
thylation of certain genomic regions. Joanna Wysocka
(Stanford University School of Medicine, USA) spoke about
the human endogenous retrovirus group K (HERV-K)
family of transposable elements, which retain open read-
ing frames and are usually hypermethylated in human
somatic cells. DNA hypomethylation and octamer-binding
transcription factor 4 expression in the human embryo
acted synergistically to promote the expression of
HERV-K full-length transcripts, and virus-like particles
in the blastocyst were detectable by electron microscopy.
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to protect the developing embryo from infection by ex-
ogenous viruses and active endogenous retroviruses.
Several speakers highlighted new techniques in this area
of research. L Stirling Churchman (Harvard Medical
School, USA) reported that RNA polymerase is a
uniquely sensitive ‘reader’ of sequence features and epige-
nomic states. Her lab recently developed a new technique
called native elongating transcripts sequencing (NET-seq;
Table 1), which maps active RNA polymerase II in vivo.
Using this technique, widespread divergent antisense tran-
scription is detected in 77 % of all expressed genes in hu-
man cells, and convergent transcription, a characteristic of
genes that are expressed at very low levels, in 25 % of pro-
moters. Using NET-seq, RNA polymerase can detect
exons and splicing fates, while pronounced pausing is ob-
served at retained and constitutive exons, but not at alter-
natively spliced exons. Using a new low-input chromatin
immunoprecipitation sequencing (ChIP-seq) method,
Matthew Lorincz (University of British Columbia, Canada)
reported that class I and class II long terminal repeat
(LTR) retrotransposons are marked with histone H3 lysine
9 trimethylation (H3K9me3) in embryonic day 13.5 prim-
ordial germ cells, the stage in gametogenesis when DNA
methylation levels are at their lowest. As in the preimplan-
tation embryo, however, the H3K9me3-marked LTR ele-
ments are resistant to DNA demethylation. By using a
germ line-specific conditional KO of the H3K9 histone-
lysine N-methyltransferase SETDB1, their observations
suggest that the H3K9me3 mark may promote the persist-
ence of DNA methylation during the developmental
stages, when maintaining the DNA methylation machin-
ery is tightly regulated.
Interrelated roles of non-coding RNAs and
chromatin modification
There are over 10,000 long non-coding RNAs (lncRNAs)
in humans and mice, with many affecting gene expres-
sion. Several talks in this session addressed the major
questions surrounding lncRNA activity related to chro-
matin modifications. One of the standout talks in this
group was given by Mitchell Guttman (California Insti-
tute of Technology, USA), who reported on his lab’s
studies of Xist lncRNA localization, spreading and silen-
cing across the X chromosome. Continuing the theme of
emerging technology, the Guttman lab developed a
novel method called RNA antisense purification (RAP;
Table 1), which allows genome-wide localization of a
lncRNA, and applied this method to study the localization
of the Xist lncRNA in a doxycycline-inducible cell culture
system. They were able to determine that Xist localizes to
initial target sites based on the three-dimensional struc-
ture of the X chromosome. By adapting the RAP method
to enable comprehensive detection of the proteins thatassociate with Xist, Guttman showed that silencing the X
chromosome requires a set of proteins, including a large
scaffold protein called SHARP, which silences transcrip-
tion by interacting with histone deacetylase 3 (HDAC3) to
evict RNA polymerase II from chromatin. Overall, their
very comprehensive studies suggest a model whereby Xist
and other lncRNAs may act as regulatory scaffolds to
localize chromatin and regulate transcription at target
sites.
Other talks in these sessions focused on the activity of
small non-coding RNAs. Natasha Weiser (University of
Michigan, USA) presented work in Caenorhabditis ele-
gans, where MORC-1 protein regulates the balance of
active and silent chromatin by binding euchromatin,
promoting the removal of activation marks such as
H3K4me3, and allowing the deposition of repressive
H3K9me3 marks by the nuclear RNA interference (RNAi)
pathway. Loss of critical components of the RNAi pathway
lead to the transgenerational loss of H3K9me3 at target
genes.
Genomic imprinting
Another significant session of the conference focused on
emerging research in genomic imprinting, the epigenetic
mechanism by which certain genes are expressed in a
parent-of-origin-specific manner. Anne Ferguson-Smith
(University of Cambridge, UK) reported that the main-
tenance of methylation at imprinting control regions
(ICRs) during the widespread demethylation that occurs
in the zygotic preimplantation embryo occurs via the
binding of the Krüppel-associated box (KRAB)-zinc
finger protein 57 (ZFP57) to methylated alleles of ICRs.
Maternal-zygotic mutation of the Zfp57 gene (that
is, homozygous embryos derived from homozygous
eggs) leads to rapid loss of imprints during zygotic
reprogramming.
Epigenetics of disease, epigenetic biomarkers and
therapeutics
Epigenetic alterations occur very frequently in cancer,
and epigenetic marks can also be exploited for their
prognostic or diagnostic value as biomarkers. Peter Jones
(Van Andel Research Institute, USA) used a new nu-
cleosome occupancy and methylome sequencing assay
(NOMe-seq; Table 1) developed in combination with
ChIP-seq to analyze cancers in patients treated with
DNMT inhibitors, revealing reorganization of nucleo-
some positioning-phasing accompanying DNA methyla-
tion loss in CpG island (CGI) promoters, in association
with gene activation. Interestingly, phasing around CTCF
binding sites remains largely unaffected in response to
DNA demethylation events in cancer. Peter Laird (Van
Andel Research Institute, USA) updated research to define
the CGI methylator phenotype (CIMP) from analyses
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ning 12 cancer types. Genes previously not known to be
epigenetically silenced were identified, as well as being
integrated with other levels of information (such as the
presence of common DNA mutations) to enhance the
value of CIMPs. He also described a mouse model
where engineered mice with an inducible repression of
DNMT1 were crossed with APCmin mice, which sup-
pressed intestinal polyp formation through transcriptional
regulation of DNMT1. Stephan Beck (University College
London, UK) presented data on epigenetic biomarkers for
two different conditions. The first was a predictive bio-
marker for severe acute graft-versus-host disease (GVHD)
in healthy donors prior to haematopoietic stem cell trans-
plantation. This marker has been validated in the lab and
a large-scale study is now under way. The second was a
predictive biomarker for differentiation capacity following
reprogramming of adult cells into induced pluripotent
stem cells (iPSCs) using Yamanaka factors and differen-
tiating iPSCs into the endoderm lineage. Surprisingly,
Beck’s team found that non-CpG methylation patterns
are a better biomarker for this than traditional CpG
methylation.
Pluripotency and stem cells
Epigenetics is a key area of study in the fields of pluri-
potency and stem cell research, and several interesting
talks in this session addressed ongoing experiments
related to how epigenetic marks are dynamic and func-
tional throughout the process of stem cell differenti-
ation. Wolf Reik (Babraham Institute, UK) outlined
evidence that ESCs undergo epigenetic priming by de
novo methylation as they transit out of naive pluripo-
tency. Based on the fact that these cells express high
levels of DNMT3 and ten-eleven translocation en-
zymes, he proposed that continuous reprogramming
might create epigenetic heterogeneity in the cell popu-
lation. Single-cell DNA methylation analysis revealed
that enhancers (marked by H3K4me1) and low CpG
content promoters are the most variably methylated
genomic elements in ESCs. Variable methylation in
regulatory elements is associated with variable tran-
scription as assessed by single-cell RNA sequencing.
They are now addressing the question whether a simi-
lar system operates in vivo in the embryo during gas-
trulation. Bradley Cairns (HHMI/University of Utah,
USA) reported that in spermatogonial stem cells and
sperm, the promoters or enhancers of Nanog, Prdm14
and Sox2, which are silent in spermatogonial stem cells
and adult germ line stem cells, bear particular chroma-
tin and DNA methylation attributes that may ‘poise’
them for reactivation after fertilization, and which may
underlie their spontaneous ability to form ES-like cells
in vitro. They also observed this ‘poising or bivalency’at the promoters of many embryonic transcription factors
in the germ line, which may enable their expression in
embryos.
Several other talks focused on how epigenetic marks
may be altered in disease. Margaret Goodell (Baylor
College of Medicine, USA) discussed epigenetic develop-
ment of the haemopoietic system. DNMT3A mutations
are associated with approximately 20 % of certain types
of haematological malignancies. DNMT3A conditional
KO mice carry out haematopoiesis at a greater rate than
wild-type mice, whereas DNMT3B KO diminishes blood
production. Haemopoietic differentiation in double KOs
is almost completely blocked, mediated in part by sta-
bilized beta-catenin protein. Mice transplanted with
DNMT3A KO haemopoietic stem cells all develop
haematological malignancies within approximately
400 days, with pathological characteristics similar to
haematological malignancies in patients with DNMT3A
mutations. Jeanne Loring (The Scripps Research Institute,
USA) described reprogramming of iPSCs derived from
fragile X syndrome patients to develop a therapy for these
patients. Cells carrying a fragile X mutation have DNA
methylation at the fragile X mental retardation 1 (Fmr1)
locus, but due to somatic mosaicism it is possible to iden-
tify cells with expanded repeats that are unmethylated at
the Fmr1 gene; Fmr1 methylation-negative iPSCs dif-
ferentiate into neurons with a slight developmental
delay compared to wild-type iPSCs. Some genes, in-
cluding autism-associated genes, are more frequently
affected in neuronally differentiated iPSCs from fragile
X syndrome patients.
Concluding remarks
This meeting covered many new developments and con-
cepts in the field of DNA methylation and epigenomics.
However, due to the large number of extremely interest-
ing and high-quality talks, as well as posters presented at
the meeting, this report only gives a brief glimpse of the
whole meeting, and unfortunately we could not include
many other excellent presentations. In addition, we have
reported a number of new and very exciting techno-
logical developments (Table 1); as a result, it is very
likely that there will be much exciting research occurring
in this field in the very near future.
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